MedTrace Logo

A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors

NCT07159828 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-05-06

No results posted yet for this study

Summary

The goal of this clinical trial is to learn more about the side effects and best dose of AXN-2510 in adults with advanced solid tumors. The main questions it aims to answer are:

* What are the side effects of AXN-2510?
* Which is the best tolerated dose of AXN-2510?
* How long does AXN-2510 stay in your body?

Participants will receive AXN-2510 every 3 weeks. Participants will visit the clinic for checkups and tests several days during the first and third doses, and once every 3 weeks for other doses.

Conditions

  • Solid Tumor, Adult

Interventions

BIOLOGICAL

AXN-2510

AXN-2510 is an antibody with PD-L1 blocking and VEGF inhibition activity in one drug. This is called a bispecific antibody, because it has 2 activities. This immuno-oncology treatment is in development for the treatment of solid tumors. AXN-2510 is differentiated from other PD-L1 and VEGF bispecific antibodies by its ability to inhibit multiple VEGF molecules and also increased antibody-dependent cellular cytotoxicity (ADCC) that can directly kill PD-L1-positive tumor cells.

Sponsors & Collaborators

  • Instil Bio

    collaborator INDUSTRY

  • Axion Bio, Inc

    lead INDUSTRY

Principal Investigators

  • Jill I Loftiss, RN · Instil Bio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-15
Primary Completion
2026-04-16
Completion
2026-04-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07159828 on ClinicalTrials.gov